BioPorto
0.89 DKK
+2.77 %
Less than 1K followers
BIOPOR
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.77 %
-1.77 %
-12.84 %
-12.84 %
-31.40 %
-35.77 %
-47.48 %
-83.25 %
-62.68 %
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
440.15M DKK
Turnover
629.29K DKK
Revenue
40.29M
EBIT %
-213.7 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2026-04-01
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
24/4
2026
General meeting '26
21/5
2026
Interim report Q1'26
20/8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Notice convening the Annual General Meeting in BioPorto A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
